This technology is a brain-computer interface system for controlling motor commands that can generalize across different movements and contexts for an efficient brain-computer interface communication method.
This technology is a targeted approach to modulate neuroproteasome activity, enabling precise regulation of Tau aggregation in Alzheimer’s disease and related neurodegenerative disorders.
This technology is a biologic platform that enhances SUMO2 conjugation to preserve or restore synaptic function and memory in Alzheimer’s disease (AD) without altering amyloid burden.
